Good news has come to light for patients in the battle against cholesterol. An experimental trial by Sanofi and Regeneron Pharmaceuticals has proven to cut the number of heart attacks and strokes almost in half. The clinical trial was analysed retrospectively, which means the results are not yet conclusive, but it’s still huge news for millions of patients that suffer from cardio-vascular risk — a disease directly linked to high cholesterol. The injectable drug is called alirocumab. It targets a protein called PCSK9 and lowers LDL, which can simply be described as the bad cholesterol in our bodies. Amgen and Pfizer are developing similar drugs which may be on the market as early as next year, netting the companies millions in profit if approved with patients lining up to lower their chances of heart disease. The study has been named Odyssey Long Term, and it’s still underway with 2,341 patients participating. Read more http://www.savingadvice.com/articles/2014/09/01/1027516_cholesterol-drug-alirocumab.html
